Shares of telehealth platform operator Hims & Hers Health (NYSE:HIMS) are soaring high in the pre-market session today after the company posted impressive third-quarter numbers.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Revenue surged a massive 95.3% year-over-year to $144.84 million, cruising past estimates by $14.5 million. Net loss per share at $0.09 too came in narrower than expectations by $0.01.
The company’s focus on consumers helped it net over 100,000 net new subscriptions during this period, taking the total tally to 991,000 subscriptions at the end of Q3.
Further, buoyed by scale and operating leverage, the company has upped its full-year outlook and expects adjusted EBITDA profitability in the fourth quarter.
For the full-year 2022, revenue is anticipated between $519 million and $522 million. Adjusted EBITDA loss is expected to hover between $20 million and $18 million.
Further, adjusted EBITDA for the fourth quarter is seen landing between $0 million and $2 million.
Read full Disclosure
